ArticlePituitary2026
Symptom severity and exacerbation frequency in medically treated patients with acromegaly.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTo quantify the severity, frequency of symptom exacerbations, and associated life impact of acromegaly symptoms in patients treated with injected depot somatostatin receptor ligands (SRLs).
methodsPatients receiving depot SRLs completed daily 24-hour recall surveys for 3 months. The daily surveys assessed the severity of 7 core symptoms and 2 additional symptoms on numeric scales (0-10). Symptom exacerbation was defined as a ≥ 2-point increase in any symptom score, comparing the current 2-day average with the prior 2-day average. Patients completed a final survey assessing 3-month recall of symptom severity and daily functioning, treatment satisfaction, and healthcare resource utilization (HCRU).
resultsThe analysis population included 31 patients: mean (SD) age was 53.4 (13.6) years; 24 (77.4%) were female; 15 (48.4%) were receiving SRL monotherapy and 16 (51.6%) SRL plus non-SRL therapy. Three-month recall overestimated symptom severity relative to daily ratings and did not capture exacerbation frequency. Symptom exacerbations assessed via daily surveys occurred, on average, on 32.1% of days (> 2 days/week) throughout the injection cycle. Greater total and individual symptom severity and exacerbation frequency were related to greater life interference, including impaired daily activities, reduced work productivity, reduced treatment satisfaction, diminished life satisfaction, and increased HCRU.
conclusionIn patients with acromegaly treated with injected depot SRLs, symptom exacerbations occurred frequently. Symptom severity and exacerbation frequency were associated with impaired daily functioning and reduced life satisfaction. A simple daily symptom assessment provides clinically meaningful information about adequacy of disease control that is not captured by longer-term recall.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.